- Previous Close
2.5000 - Open
2.5000 - Bid 2.5000 x 165400
- Ask 3.0000 x 161000
- Day's Range
2.5000 - 2.5000 - 52 Week Range
2.0700 - 9.7000 - Volume
20 - Avg. Volume
376 - Market Cap (intraday)
76.361M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7600 - Earnings Date Apr 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
www.4sc.comRecent News: VSC.F
View MorePerformance Overview: VSC.F
Trailing total returns as of 4/6/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VSC.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VSC.F
View MoreValuation Measures
Market Cap
25.29M
Enterprise Value
16.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
81.59
Price/Book (mrq)
35.22
Enterprise Value/Revenue
50.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.35%
Return on Equity (ttm)
-288.87%
Revenue (ttm)
347k
Net Income Avi to Common (ttm)
-8.33M
Diluted EPS (ttm)
-0.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
8.31M
Total Debt/Equity (mrq)
961.98%
Levered Free Cash Flow (ttm)
-5.28M